The University of Chicago Header Logo

Connection

Yusuke Nakamura to Breast Neoplasms

Back to Details
This is a "connection" page, showing publications Yusuke Nakamura has written about Breast Neoplasms.
Yusuke Nakamura
Connection Strength
5.093
Breast Neoplasms
  1. The GALNT6-LGALS3BP axis promotes breast cancer cell growth. Int J Oncol. 2020 Feb; 56(2):581-595.
    View in: PubMed
    Score: 0.274
  2. Critical Role of Estrogen Receptor Alpha O-Glycosylation by N-Acetylgalactosaminyltransferase 6 (GALNT6) in Its Nuclear Localization in Breast Cancer Cells. Neoplasia. 2018 10; 20(10):1038-1044.
    View in: PubMed
    Score: 0.251
  3. Breast cancer: The translation of big genomic data to cancer precision medicine. Cancer Sci. 2018 Mar; 109(3):497-506.
    View in: PubMed
    Score: 0.239
  4. Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study. Clin Cancer Res. 2017 04 15; 23(8):2019-2026.
    View in: PubMed
    Score: 0.220
  5. Phosphatidylinositol glycan anchor biosynthesis, class X containing complex promotes cancer cell proliferation through suppression of EHD2 and ZIC1, putative tumor suppressors. Int J Oncol. 2016 Sep; 49(3):868-76.
    View in: PubMed
    Score: 0.216
  6. Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int J Oncol. 2016 Aug; 49(2):471-8.
    View in: PubMed
    Score: 0.214
  7. A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients. Breast Cancer Res. 2013; 15(5):R81.
    View in: PubMed
    Score: 0.169
  8. A genome-wide association study identifies a genetic variant in the SIAH2 locus associated with hormonal receptor-positive breast cancer in Japanese. J Hum Genet. 2012 Dec; 57(12):766-71.
    View in: PubMed
    Score: 0.166
  9. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst. 2012 Aug 22; 104(16):1264; author reply 1266-8.
    View in: PubMed
    Score: 0.165
  10. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen? Expert Rev Anticancer Ther. 2011 Feb; 11(2):185-93.
    View in: PubMed
    Score: 0.148
  11. Critical involvement of RQCD1 in the EGFR-Akt pathway in mammary carcinogenesis. Int J Oncol. 2010 Nov; 37(5):1085-93.
    View in: PubMed
    Score: 0.146
  12. Critical roles of LGN/GPSM2 phosphorylation by PBK/TOPK in cell division of breast cancer cells. Genes Chromosomes Cancer. 2010 Oct; 49(10):861-72.
    View in: PubMed
    Score: 0.145
  13. Involvement of C12orf32 overexpression in breast carcinogenesis. Int J Oncol. 2010 Oct; 37(4):861-7.
    View in: PubMed
    Score: 0.145
  14. Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells. Int J Oncol. 2009 Oct; 35(4):673-81.
    View in: PubMed
    Score: 0.135
  15. Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling. Int J Oncol. 2009 Feb; 34(2):361-70.
    View in: PubMed
    Score: 0.129
  16. Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol. 2004 Oct; 25(4):797-819.
    View in: PubMed
    Score: 0.096
  17. Gene expression patterns as marker for 5-year postoperative prognosis of primary breast cancers. J Cancer Res Clin Oncol. 2004 Sep; 130(9):537-45.
    View in: PubMed
    Score: 0.094
  18. Association of allelic loss at 8p22 with poor prognosis among breast cancer cases treated with high-dose adjuvant chemotherapy. Cancer Lett. 2002 Jun 06; 180(1):75-82.
    View in: PubMed
    Score: 0.081
  19. Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer. Cancer Sci. 2022 May; 113(5):1808-1820.
    View in: PubMed
    Score: 0.080
  20. Functional genomics for breast cancer drug target discovery. J Hum Genet. 2021 Sep; 66(9):927-935.
    View in: PubMed
    Score: 0.077
  21. Neoantigens elicit T cell responses in breast cancer. Sci Rep. 2021 06 30; 11(1):13590.
    View in: PubMed
    Score: 0.076
  22. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. Cancer Sci. 2021 Jan; 112(1):454-464.
    View in: PubMed
    Score: 0.073
  23. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2020 Apr; 180(2):331-341.
    View in: PubMed
    Score: 0.069
  24. Identification of two novel breast cancer loci through large-scale genome-wide association study in the Japanese population. Sci Rep. 2019 11 22; 9(1):17332.
    View in: PubMed
    Score: 0.068
  25. Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM. J Clin Oncol. 2019 08 01; 37(22):1982-1983.
    View in: PubMed
    Score: 0.066
  26. SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. Breast Cancer Res Treat. 2017 Jul; 164(1):189-199.
    View in: PubMed
    Score: 0.057
  27. Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project. J Epidemiol. 2017 Mar; 27(3S):S58-S64.
    View in: PubMed
    Score: 0.056
  28. Germline PARP4 mutations in patients with primary thyroid and breast cancers. Endocr Relat Cancer. 2016 Mar; 23(3):171-9.
    View in: PubMed
    Score: 0.052
  29. A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. Breast Cancer Res Treat. 2015 Jan; 149(2):517-23.
    View in: PubMed
    Score: 0.049
  30. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst. 2014 Dec 08; 107(2).
    View in: PubMed
    Score: 0.048
  31. Identification of novel epigenetically inactivated gene PAMR1 in breast carcinoma. Oncol Rep. 2015 Jan; 33(1):267-73.
    View in: PubMed
    Score: 0.048
  32. Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nat Genet. 2014 Aug; 46(8):886-90.
    View in: PubMed
    Score: 0.047
  33. VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Res. 2014 May 28; 16(3):R53.
    View in: PubMed
    Score: 0.047
  34. Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst. 2014 Apr 03; 106(5).
    View in: PubMed
    Score: 0.046
  35. Genome-wide association study of breast cancer in the Japanese population. PLoS One. 2013; 8(10):e76463.
    View in: PubMed
    Score: 0.045
  36. CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality. Clin Pharmacol Ther. 2013 Aug; 94(2):185-7.
    View in: PubMed
    Score: 0.044
  37. Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov. 2013 Jul; 3(7):812-25.
    View in: PubMed
    Score: 0.044
  38. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies. J Hum Genet. 2013 Jun; 58(6):327-33.
    View in: PubMed
    Score: 0.043
  39. Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis. Int J Oncol. 2013 Feb; 42(2):478-506.
    View in: PubMed
    Score: 0.042
  40. PKIB expression strongly correlated with phosphorylated Akt expression in breast cancers and also with triple-negative breast cancer subtype. Med Mol Morphol. 2012 Dec; 45(4):229-33.
    View in: PubMed
    Score: 0.042
  41. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res. 2013 Jan 15; 19(2):491-9.
    View in: PubMed
    Score: 0.042
  42. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res. 2012 Sep 15; 18(18):5099-109.
    View in: PubMed
    Score: 0.041
  43. A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet. 2012 Apr 01; 21(7):1665-72.
    View in: PubMed
    Score: 0.039
  44. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res Treat. 2012 Jan; 131(1):137-45.
    View in: PubMed
    Score: 0.039
  45. Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin Cancer Res. 2011 Nov 01; 17(21):6944-51.
    View in: PubMed
    Score: 0.039
  46. Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin. Neoplasia. 2011 Apr; 13(4):320-6.
    View in: PubMed
    Score: 0.038
  47. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol. 2010 Nov 01; 28(31):4674-82.
    View in: PubMed
    Score: 0.036
  48. Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res. 2010 Apr 01; 70(7):2759-69.
    View in: PubMed
    Score: 0.035
  49. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010 Mar 10; 28(8):1287-93.
    View in: PubMed
    Score: 0.035
  50. Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration. World J Surg Oncol. 2009 Nov 12; 7:88.
    View in: PubMed
    Score: 0.034
  51. Ubiquitination and downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T overexpression in human breast cancer cells. Cancer Res. 2009 Nov 15; 69(22):8752-60.
    View in: PubMed
    Score: 0.034
  52. Critical roles of T-LAK cell-originated protein kinase in cytokinesis. Cancer Sci. 2010 Feb; 101(2):403-11.
    View in: PubMed
    Score: 0.034
  53. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. J Hum Genet. 2009 Oct; 54(10):564-71.
    View in: PubMed
    Score: 0.034
  54. Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer. Cancer Sci. 2009 Aug; 100(8):1468-78.
    View in: PubMed
    Score: 0.033
  55. Involvement of G-patch domain containing 2 overexpression in breast carcinogenesis. Cancer Sci. 2009 Aug; 100(8):1443-50.
    View in: PubMed
    Score: 0.033
  56. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci. 2008 May; 99(5):995-9.
    View in: PubMed
    Score: 0.030
  57. Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. Cancer Sci. 2008 Jan; 99(1):62-70.
    View in: PubMed
    Score: 0.030
  58. Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. Cancer Sci. 2007 Feb; 98(2):174-81.
    View in: PubMed
    Score: 0.028
  59. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family. Breast Cancer Res. 2007; 9(1):R17.
    View in: PubMed
    Score: 0.028
  60. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res. 2006 Sep 15; 66(18):9186-95.
    View in: PubMed
    Score: 0.027
  61. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006 Feb; 97(2):113-8.
    View in: PubMed
    Score: 0.026
  62. ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene. 2004 Oct 07; 23(46):7601-10.
    View in: PubMed
    Score: 0.024
  63. Identification of semaphorin3B as a direct target of p53. Neoplasia. 2002 Jan-Feb; 4(1):82-7.
    View in: PubMed
    Score: 0.020
  64. Correlation of allelic losses and clinicopathological factors in 504 primary breast cancers. Breast Cancer. 2002; 9(3):208-15.
    View in: PubMed
    Score: 0.020
  65. Cystatin C as a p53-inducible apoptotic mediator that regulates cathepsin L activity. Cancer Sci. 2016 Mar; 107(3):298-306.
    View in: PubMed
    Score: 0.013
  66. A rare polymorphic variant of NBS1 reduces DNA repair activity and elevates chromosomal instability. Cancer Res. 2014 Jul 15; 74(14):3707-15.
    View in: PubMed
    Score: 0.012
  67. TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol Endocrinol. 2013 Apr; 27(4):657-70.
    View in: PubMed
    Score: 0.011
  68. Genome-wide association study of epirubicin-induced leukopenia in Japanese patients. Pharmacogenet Genomics. 2011 Sep; 21(9):552-8.
    View in: PubMed
    Score: 0.010
  69. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet Genomics. 2010 Sep; 20(9):565-8.
    View in: PubMed
    Score: 0.009
  70. Herpes simplex virus-induced, death receptor-dependent apoptosis and regression of transplanted human cancers. Cancer Sci. 2004 Dec; 95(12):990-8.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.